Baxter International Inc. Earnings Recaps
Q1 2026
May 4, 2026
Baxter's shares rose 1.8% following a first quarter report that met expectations, with organic sales declining slightly but partially offset by growth in Advanced Surgery and ongoing innovation efforts. Despite margin pressures and challenging comps, the market reaction was modestly positive, reflecting cautious optimism on the company’s turnaround progress.
Key takeaways
- Reported sales increased 3% year-over-year to $2.7 billion, but organic sales declined 1%, reflecting underlying demand softness.
- Adjusted EPS fell to $0.36 from $0.55 a year ago, pressured by tariff impacts, higher manufacturing costs, and unfavorable prior year comparables.
- Advanced Surgery segment delivered strong order growth and expanded 10% in the quarter, supporting growth outlook.
- Management highlighted progress on addressing infusion pump hardware and software issues, with ongoing regulatory coordination and mitigations in place.
- Innovation efforts include new product launches with AI enhancements and digital connectivity solutions aimed at improving clinical outcomes and operational efficiency.
Q3 2025
Oct 31, 2025
Baxter International's Q3 2025 results showed lower-than-expected revenue but exceeded earnings forecasts driven by a favorable tax rate, while new CEO Andrew Hider emphasizes a commitment to operational improvements and financial health.
Key takeaways
- Revenue performance fell short of guidance primarily due to challenges in the Infusion Therapies & Technologies and Pharmaceuticals divisions.
- The Healthcare Systems & Technologies segment showed improved performance, indicating potential resilience in key areas.
- The company plans to stabilize underperforming divisions, strengthen its balance sheet, and cultivate a culture of continuous improvement.
- Baxter aims to address operational issues, particularly regarding the Novum IQ Large Volume pump, which faces a delivery hold due to flow rate concerns.
- Moving forward, a clear focus on cash flow improvement and reducing leverage is prioritized to support growth and shareholder returns.